Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 35-year-old man developed avascular necrosis after receiving intradermal corticosteroid injections for alopecia areata, marking the first documented instance of this side effect from such treatment.

The document honored Yvonne, announced upcoming dermatology events, and introduced new journal editors.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Photodynamic therapy was effective in treating multiple scalp basal cell carcinomas with minimal side effects and good cosmetic results.

This guideline reviews the diagnosis and treatment of malignant cutaneous angiosarcomas, highlighting the complexity of treatment and the importance of early detection despite non-specific clinical presentations.

This study found that nearly all nurses caring for chemotherapy patients showed detectable levels of cyclophosphamide in their urine, indicating significant occupational exposure to this antineoplastic drug.

This review covers the molecular basis of Birt–Hogg–Dubé syndrome and its implications for potential therapeutic targets, but it does not report new experimental results.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This case report suggests an immunological link between multifocal acquired demyelinating sensory and motor neuropathy and alopecia, with both conditions improving after treatment with intravenous immunoglobulin.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

This study suggests that macrophages, particularly CD206⁺ macrophages, play a crucial role in squaric acid dibutylester-induced hair growth in alopecia areata treatment.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

This case study reported a 23-year-old woman with chronic myeloid leukemia who developed permanent hair loss after chemotherapy and did not respond to topical minoxidil treatment.

This study found that CD44 and CD49d together enhance signaling pathways in lymphocytes in mice with alopecia areata, influencing their activation and function.

This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.

This study found that venous blood ammonia levels, particularly in patients taking valproate combined with other antiepileptic drugs, were significantly elevated compared to those on valproate alone.

This study investigated vitamin D receptor expression in normal hair follicles and those affected by alopecia areata, focusing on various markers using immunohistochemical staining.

This review discusses the role of the BAFF system in autoimmune diseases and highlights its therapeutic potential, emphasizing the need for disease-specific clinical trials to improve treatment strategies.

This study found that the medicinal formula YH0618 may reduce toxicity from the chemotherapy drug doxorubicin, improving side effects like hair loss and organ damage, while maintaining its anti-cancer effects.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This study found that vinegar-processed black soybean and its extract accelerated hair growth and prevented alopecia in mice, with potential mechanisms involving modulation of the Wnt/β-catenin signaling pathway, suggesting they may be promising functional foods for hair regeneration.

This letter discusses a case of hapten-induced lymphadenosis benigna cutis following sensitization with squaric acid dibutylester for treating alopecia areata and reports no new clinical results.

This abstract provides no new research findings; it appears to be text related to the American Society of Plastic Surgeons' educational resources.

This case report highlights a rare instance of diffuse alveolar hemorrhage in a patient with catastrophic antiphospholipid syndrome, emphasizing the importance of early recognition and multidisciplinary management.

This study found that Cannabidivarin (CBDV) promotes neuronal survival, proliferation, and differentiation via TRPV1 activation but inhibits oligodendrocyte differentiation in postnatal neurogenesis.

This study found that the computer-controlled RV-01 scalp cooling device helped prevent significant hair loss in metastatic breast cancer patients treated with eribulin, with none of the 16 patients requiring a wig and experiencing minimal discomfort.

This case report documents a female toddler with novel compound heterozygous mutations in the VDR gene causing hereditary 1,25-dihydroxyvitamin D-resistant rickets, expanding the known mutation spectrum for this disease.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This study observed no significant difference in vitamin D levels between children with alopecia areata and controls, but higher complete improvement in alopecia was noted among patients with vitamin D deficiency undergoing oral vitamin D treatment.